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Abstract
Background: The effect of alirocumab on potentially atherogenic lipoprotein subfractions was assessed in a post
hoc analysis using the vertical auto profile (VAP) method.
Methods: Patients from three Phase II studies with low-density lipoprotein cholesterol (LDL-C) ≥2.59 mmol/L (100
mg/dL) at baseline on stable statin therapy were randomised to receive subcutaneous alirocumab 50–150 mg every
2 weeks (Q2W) or 150–300 mg every 4 weeks (according to study) or placebo for 8–12 weeks. Samples from
patients treated with alirocumab 150 mg Q2W (n = 74; dose common to all three trials) or placebo (n = 71) were
analysed by VAP. Percent change in lipoprotein subfractions with alirocumab vs. placebo was analysed at Weeks 6,
8 or 12 using analysis of covariance.
Results: Alirocumab significantly reduced LDL-C and the cholesterol content of subfractions LDL1, LDL2 and LDL3+4.
Significant reductions were also observed in triglycerides, apolipoproteins CII and CIII and the cholesterol content of
very low-density, intermediate-density, and remnant lipoproteins.
Conclusion: Alirocumab achieved reductions across a spectrum of atherogenic lipoproteins in patients receiving
background statin therapy.
Trial registration: Clinicaltrials.gov identifiers: NCT01288443, NCT01288469, NCT01266876
Keywords: Alirocumab, Hypercholesterolaemia, Lipoprotein subfraction, PCSK9, VAP
Background
Lipoproteins consist of lipids and apolipoproteins and
can be categorised by density into five major classes:
chylomicrons, very low-density lipoprotein (VLDL), low-
density lipoprotein (LDL), intermediate-density lipoprotein
(IDL) and high-density lipoprotein (HDL) [1]. Elevated
levels of LDL cholesterol (LDL-C) are a well-established
risk factor for the development of cardiovascular disease
[2]. LDL-C is composed of a spectrum of LDL particles of
different densities and states of lipidation, all of which are
atherogenic [3]. Levels of the most dense LDL-C particles
may be disproportionately raised in patients with low HDL
cholesterol (HDL-C) and high triglycerides [4]. Analysis of
changes in LDL subfractions may provide additional infor-
mation to help direct individual patient treatment [5], al-
though it is currently not recommended in guidelines [6].
In addition to LDL-C, triglyceride-rich remnant lipo-
proteins (RLP) are also atherogenic [4]. RLPs are prod-
ucts of VLDL lipolysis, and include VLDL3 (the smallest
and most dense particles of the VLDL subclass) and
IDLs (the direct precursor to LDL formation). Serum
concentration of RLPs are often increased in patients
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with elevated triglyceride levels, such as those with lipo-
protein lipase deficiency, insulin resistance, and metabolic
syndrome. Two important regulators of triglyceride levels
are apolipoprotein (apo) CII and CIII. ApoCIII inhibits
lipoprotein lipase-mediated catabolism of VLDL triglycer-
ides [7]. ApoCII appears to have a more complex relation-
ship with VLDL and lipoprotein lipase activity that may
depend on baseline triglyceride levels, and is generally an
important activator of lipoprotein lipase [8].
Ultracentrifugation is the standard for direct measurement
of LDL-C levels, as Friedewald calculation frequently under-
estimates LDL-C at levels <100 mg/dL or in the setting of
elevated triglycerides [9]. Vertical auto profiling (VAP), a
rapid and highly sensitive direct ultracentrifugation method,
provides measurements of lipoproteins and subfractions not
assessed using standard techniques [10–12].
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
regulates levels of the LDL receptor [13]. Alirocumab is
a fully human monoclonal antibody to PCSK9 which sig-
nificantly reduced LDL-C levels in clinical trials, with
overall adverse events comparable to control [14–19]. In
addition, significant reductions in apoB, non-HDL-C and
lipoprotein(a), trends for reduction in triglycerides, and
modest increases in HDL-C and apoAI, were observed.
PSCK9 exerts complex regulatory functions on lipo-
protein metabolism [13]. PCSK9 inhibition correlates
with substantial reduction in serum LDL-C levels
[14–19]. We hypothesized that these large reductions
in LDL-C would coincide with reductions in serum
levels of all apoB-containing lipoproteins including
remnant lipoproteins, possibly because of increased
clearance of these lipoproteins by increased availability
of LDL receptors.
Using VAP testing, a post hoc analysis of three alirocu-
mab Phase II trials was performed to determine if the sig-
nificant reductions in LDL-C observed with alirocumab
were reflected by reductions across the spectrum of athero-
genic LDL subfractions, and to determine the impact on
other lipoproteins such as IDL cholesterol (IDL-C) and
VLDL cholesterol (VLDL-C).
Results
In the three Phase II trials, 108 patients received alirocu-
mab 150 mg Q2W and 77 received placebo. Baseline
characteristics from these patients are shown in Table 1.
Baseline and post-treatment samples were available for
VAP analysis from 100 alirocumab patients and 71 placebo
patients.
LDL-C and subfractions
Significant reductions in the cholesterol content of LDL
and LDL1–3-C were observed in patients receiving aliro-
cumab vs. placebo (Table 2). Baseline levels of the dens-
est LDL subfraction (LDL4-C) were relatively very low.
Percentage changes in levels of LDL4-C were inconsist-
ent between studies, with high standard deviation values,
although absolute reductions in LDL4-C were significant
vs. placebo for all alirocumab groups (Table 2). When
LDL4-C was assessed in a pooled analysis with LDL3-C
(as LDL3+4-C; the two densest subfractions), mean reduc-
tions of 68.5, 55.2 and 48.8 % were observed in studies
565, 566 and 1003, respectively (p < 0.0001 vs. placebo).
Table 1 Baseline characteristics
Placebo (n = 77) Alirocumab 150 mg Q2W (n = 108)
Age, mean (SD), years 53.8 (9.4) 58.2 (10.1)
Males, % 49.4 43.5
Race, %
White 84.4 88.9
Black or African American 13.0 11.1
Other 2.6 0
Body mass index, mean (SD), kg/m2 28.9 (4.7) 29.2 (4.6)
Lipid parameters (determined by conventional methods), mean (SD), mg/dL
LDL-C 130.6 (27.5) 127.2 (25.0)
Total cholesterol 210.5 (32.1) 208.0 (30.5)
HDL-C 51.8 (13.8) 53.8 (15.0)
Non-HDL-C 158.7 (30.8) 154.2 (31.3)
Triglycerides, median (Q1:Q3) 122.5 (91.5–174.0) 123.5 (87.8–168.5)
Apolipoprotein B 108.8 (22.8) 108.1 (23.9)
Lipoprotein (a), median (Q1:Q3) 19.0 (6.0–77.0) 28.0 (9.0–70.0)
Pooled patients from placebo and alirocumab 150 mg Q2W groups of three Phase II studies. To convert cholesterol values to mmol/L, multiply by 0.02586; to
convert triglycerides to mmol/L, multiply by 0.01129
Q2W every 2 weeks, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation
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Table 2 Changes from baseline in cholesterol content of LDL subfractions
Study 565 Study 566a Study 1003
Placebo Alirocumab 150 mg Q2W Placebo + ATV
80 mg
Alirocumab 150 mg
Q2W + ATV 10 mg
Alirocumab 150 mg
Q2W + ATV 80 mg
Placebo Alirocumab 150 mg Q2W
n = 31 n = 29 n = 26 n = 26 n = 29 n = 14 n = 16
Total LDL-C
Baseline 115.2 (27.3) 109.6 (24.8) 120.1 (24.4) 123.0 (24.0) 122.1 (33.4) 141.4 (34.1) 135.7 (28.2)
Post-treatmentb 111.1 (25.1) 34.5 (14.9) 97.7 (37.7) 43.5 (15.3) 44.6 (25.5) 130.4 (32.0) 53.4 (34.2)
% change from baseline −1.1 (21.3) −67.5 (13.6)** −17.3 (29.9) −64.6 (11.9)** −62.2 (22.5)** −6.9 (13.7) −60.3 (25.8)**
LDLr-C
Baseline 90.5 (25.0) 85.6 (22.5) 95.0 (22.3) 96.9 (21.7) 96.0 (29.2) 110.3 (28.9) 103.6 (24.1)
Post-treatmentb 87.2 (21.6) 21.5 (12.5) 75.9 (32.4) 27.7 (12.6) 29.6 (22.5) 100.6 (24.4) 36.8 (29.9)
% change from baseline 0.1 (24.6) −74.9 (14.4)** −18.6 (32.5) −71.6 (11.5)** −68.7 (22.9)** −7.1 (15.5) −64.7 (28.6)**
LDL1-C
Baseline 18.7 (6.3) 16.2 (5.6) 19.8 (7.0) 19.2 (7.7) 19.7 (9.2) 23.3 (10.2) 25.9 (9.9)
Post-treatmentb 17.0 (6.9) 3.6 (2.8) 14.7 (9.2) 5.3 (3.5) 4.9 (4.9) 21.9 (10.8) 6.8 (6.2)
% change from baseline −7.5 (24.4) −76.9 (20.8)** −18.4 (59.4) −72.5 (16.4) −40.7 (201.0) 1.0 (39.1) −68.9 (41.3)**
LDL2-C
Baseline 22.3 (11.7) 20.3 (10.9) 29.4 (13.8) 24.5 (12.3) 27.6 (15.6) 30.7 (17.5) 31.5 (17.1)
Post-treatmentb 17.8 (12.5) 3.0 (4.4) 21.5 (16.1) 4.5 (4.9) 5.5 (8.4) 27.5 (13.7) 7.8 (11.9)
% change from baseline 2.9 (140.9) −84.2 (26.2)* −24.7 (48.5) −83.7 (13.0)** −83.4 (20.0)** −2.6 (39.1) −77.9 (26.1)**
LDL3-C
Baseline 39.1 (15.2) 37.1 (13.5) 37.6 (14.8) 40.6 (14.0) 37.2 (16.4) 43.7 (13.2) 36.6 (12.5)
Post-treatmentb 38.2 (12.2) 9.1 (6.6) 30.5 (13.2) 11.0 (6.3) 11.7 (10.1) 39.9 (12.0) 15.2 (12.8)
% change from baseline 4.7 (31.6) −74.8 (20.4)** −5.5 (63.5) −71.5 (18.0)** −64.9 (29.7)** −5.0 (25.9) −58.1 (33.9)**
LDL4-C
Baseline 10.4 (7.1) 12.1 (9.0) 8.3 (6.4) 12.7 (8.5) 11.6 (11.6) 12.7 (9.7) 9.7 (11.4)
Post-treatmentb 14.2 (9.2) 5.8 (2.5) 9.2 (5.0) 7.0 (3.1) 7.5 (4.0) 11.2 (6.7) 7.1 (3.5)
Absolute change from baseline 3.9 (8.5) −6.2 (8.4)** 0.9 (4.7) −5.7 (6.5)* −4.1 (9.3)* −1.4 (7.5) −2.6 (9.7)*
% change from baseline 84.7 (164.0) −28.6 (56.4)* 106.2 (236.9) −5.6 (133.5) 51.3 (352.1) 12.8 (67.4) 53.7 (156.8)
LDL1+2-C
Baseline 40.9 (16.6) 36.5 (13.9) 49.1 (17.5) 43.6 (17.9) 47.2 (21.5) 54.0 (25.2) 57.4 (24.9)
Post-treatmentb 34.8 (17.8) 6.6 (6.2) 36.2 (24.2) 9.8 (7.9) 10.4 (12.0) 49.4 (21.5) 14.7 (17.6)















Table 2 Changes from baseline in cholesterol content of LDL subfractions (Continued)
LDL3+4-C
Baseline 49.5 (18.1) 49.2 (19.6) 45.9 (18.0) 53.2 (18.0) 48.8 (26.1) 56.4 (19.9) 46.3 (22.7)
Post-treatmentb 52.4 (15.8) 14.9 (8.1) 39.7 (14.1) 18.0 (7.8) 19.2 (13.4) 51.1 (16.1) 22.3 (14.5)
% change from baseline 15.0 (41.4) −68.5 (18.0)** −0.9 (57.9) −64.1 (18.8)** −55.2 (30.8)** −4.5 (27.3) −48.8 (31.2)**
Values are mean (SD). Units are mg/dL. *p < 0.05; **p < 0.0001. aPatients in study 566 were randomised to one of three arms and received either (1) placebo with increase in ATV dose from 10 mg to 80 mg at start of
randomised treatment period, (2) alirocumab plus ATV 10 mg, or (3) alirocumab with increase in ATV dose from 10 mg to 80 mg at start of randomised treatment period. bMeasurements occurred on Week 12 in Study
565, Week 8 in study 566 and Week 6 in study 1003. Q2W every 2 weeks, ATV atorvastatin, IDL intermediate-density lipoprotein, LDL-C low density lipoprotein cholesterol, LDLr “LDL real” [i.e. total LDL fraction minus















Reductions in LDL-C and subfractions were relatively
large in the placebo group in study 566 (where the atorva-
statin dose was increased at randomisation) compared
with the other studies (in which patients received stable
background statin therapy) (Table 2). Results were com-
parable between study 1003 (conducted in heFH patients)
and studies 565 and 566 (conducted in non-FH patients)
(Table 2). LDL-C reductions estimated using the Friede-
wald equation in the parent studies were 72.4 % (study
565), 66.2–73.2 % (study 566) and 67.9 % (study 1003;
Additional file 1: Table S1). Reductions of 67.5, 62.2–64.6
and 60.3 % were observed in directly measured LDL-C in
studies 565, 566 and 1003, respectively, and reductions of
74.9, 68.7–71.6 and 64.7 %, respectively, were observed in
LDLr-C (Table 2).
ApoB/apoA1 ratio
Levels of apoB were significantly reduced in each of the
parent studies (Additional file 1: Table S1). Changes in
the apoB/apoA1 ratio for these studies have not been re-
ported previously. The apoB/apoA1 ratio was reduced by
50.3 % in study 565, 44.5–47.4 % in study 566 and 46.3 %
in study 1003 (p < 0.0001 vs. placebo; Additional file 1:
Table S2).
VLDL-C and RLP-C
Alirocumab treatment reduced levels of VLDL-C by
26.1–32.4 % and RLP-C (VLDL3-C and IDL-C) by 42.1–
52.5 % across the studies (Table 3). Levels of VLDL sub-
fractions VLDL1+2-C and VLDL3-C were reduced by
similar amounts. Triglyceride levels were significantly re-
duced with alirocumab in studies 565 and 566 (Table 3).
Apo CII and CIII
To investigate further the observed reductions in VLDL-C,
the effect of alirocumab on serum levels of apoCII and CIII
was assessed. Reductions from baseline of 9.4–27.8 % in
apoCII and 14.5–19.1 % apoCIII were observed with aliro-
cumab treatment (Table 4). There was no difference in the
ratios of apoCII/VLDL-C or apoCIII/VLDL-C at baseline
vs. post-treatment (Additional file 1: Table S3).
Pooled analysis
A pooled analysis combining data from the three trials
was generally consistent with the individual study results
(Additional file 1: Table S4).
Discussion
Alirocumab significantly reduced cholesterol levels across
the spectrum of LDL subfractions LDL1-C, LDL2-C,
LDL3-C and the pool of LDL3+4-C (sum of smaller, denser
LDL subfractions). Notably, reductions in LDL subfractions
were overall consistent between patients with heFH and
primary hyperlipidemia. Reductions in LDL-C subfractions
in the placebo arm of study 566 were larger than the other
two studies, most likely due to the concomitant atorvastatin
dose increase from 10 mg at baseline to 80 mg at random-
isation. Small differences between the studies in terms of
the percentage change of lipoprotein parameters following
alirocumab treatment may be explained by differences in
the patient populations, e.g. baseline lipids, HeFH/non-FH,
sex distribution and background therapies [14–16].
With regards to effects on the densest LDL subfraction
(LDL4-C), significant absolute reductions were observed
in all alirocumab groups vs. placebo. Mean percentage
reductions in this parameter were inconsistent between
studies; most likely this is due to low baseline levels and
small absolute changes resulting in high levels of vari-
ation. In a randomised study, doubling the atorvastatin
dose or adding ezetimibe was reported to reduce dense
LDL particles by a lesser extent than less dense particles
[20]. One explanation for this is that the densest parti-
cles have a lower affinity for the LDL receptor [20]; how-
ever, it remains to be established why LDL4 has the
lowest levels of clearance.
The significant reduction from baseline in the ratio of
apoB/apoA1 ratio (range 45–50 % across the studies)
suggests further improvement in the atherogenic choles-
terol profile with alirocumab treatment. Multiple studies
have demonstrated that the apoB/apoA1 ratio is a more
sensitive predictor of future cardiovascular events than
individual lipoproteins or ratios of cholesterol values
[21–23]. Levels of apoB may be a more accurate pre-
dictor of cardiovascular risk than LDL-C, as apoB more
closely estimates the number of circulating LDL particles
[24]. A low level of apoA1 is also a cardiovascular risk
factor and reflects low serum levels of HDL particles [23].
Alirocumab reduced lipoprotein cholesterol across mul-
tiple atherogenic lipoprotein fractions including VLDL-C
and IDL-C. This finding is consistent with the fact that all
are apoB-containing lipoproteins, some of which may be
cleared by LDL receptors, as is LDL-C. It cannot be dis-
cerned from these data whether or not alirocumab poten-
tiates RLP clearance by increasing expression of the LDL
receptor-related protein or heparin sulfate proteoglycans,
both of which are involved in the binding and clearance of
remnants [25–27]. RLPs are products of VLDL lipolysis
and include VLDL3, the most dense VLDL subclass, and
IDL, the direct precursor of LDL [28]. There is accumulat-
ing evidence demonstrating a causal association between
elevated RLP-C levels and an increased risk of ischaemic
heart disease [28, 29]. Reductions in RLP-C with alirocu-
mab (24–44 %, placebo-corrected) appears similar if not
greater than reductions observed with statins (25 %) [30].
The reductions in apoCII and apoCIII observed in the
three studies may be a manifestation of either increased
clearance or reduced production/secretion of VLDL
particles. The observation that apoCII/VLDL-C and
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Table 3 Changes from baseline in VLDL and remnant-related lipoprotein subfractions and triglycerides
Study 565 Study 566a Study 1003
Placebo Alirocumab 150 mg Q2W Placebo + ATV 80 mg Alirocumab 150 mg
Q2W + ATV 10 mg
Alirocumab 150 mg
Q2W + ATV 80 mg
Placebo Alirocumab 150 mg
Q2W
n = 31 n = 29 n = 26 n = 26 n = 29 n = 14 n = 16
Total VLDL-C
Baseline 25.0 (20.5 to 31.5) 24.0 (18.0 to 30.0) 24.0 (20.0 to 29.0) 24.5 (21.0 to 31.0) 21.0 (17.0 to 24.0) 24.0 (18.0 to 33.0) 26.0 (18.5 to 31.5)
Post-treatmentb 24.0 (19.5 to 32.0) 17.0 (14.0 to 19.0) 20.0 (17.0 to 26.0) 20.0 (17.0 to 23.0) 16.0 (14.0 to 19.0) 27.0 (19.0 to 30.0) 16.5 (15.0 to 20.0)
% change from baseline 5.6 (−19.4 to 19.4) −32.4 (−37.1 to −17.4)** −13.5 (−26.5 to 6.7) −24.1 (−36.4 to 5.3) −26.1 (−38.7 to −10.0)* −3.6 (−12.8 to 21.4) −32.2 (−46.5 to −19.6)*
VLDL1+2-C
Baseline 10.2 (7.8 to 12.2) 9.3 (6.9 to 13.8) 9.9 (7.9 to 13.3) 10.4 (8.3 to 13.9) 7.5 (6.8 to 10.7) 9.1 (6.3 to 14.4) 10.5 (7.5 to 12.5)
Post-treatmentb 10.2 (7.9 to 14.0) 6.2 (5.1 to 7.7) 7.7 (6.5 to 11.7) 8.8 (6.7 to 10.1) 6.3 (5.3 to 8.5) 9.8 (7.7 to 11.8) 6.4 (5.4 to 8.7)
% change from baseline 12.1 (−21.9 to 27.9) −34.6 (−41.7 to −20.4)** −15.1 (−31.1 to 14.7) −18.9 (−44.6 to 10.6) −25.7 (−37.8 to −12.1)* −8.0 (−16.7 to 24.4) −33.9 (−49.5 to -–3.7)*
VLDL3-C
Baseline 15.0 (12.5 to 18.5) 14.0 (11.0 to 17.0) 14.0 (12.0 to 17.0) 14.0 (12.0 to 17.0) 12.0 (11.0 to 15.0) 14.5 (12.0 to 18.0) 15.0 (12.0 to 18.5)
Post-treatmentb 14.0 (12.0 to 18.5) 10.0 (8.0 to 12.0) 13.0 (10.0 to 15.0) 11.0 (10.0 to 13.0) 10.0 (8.0 to 11.0) 17.0 (11.0 to 18.0) 10.0 (9.0 to 12.5)
% change from baseline 0.0 (−15.5 to 15.9) −27.3 (−35.3 to −20.0)** −14.3 (−21.4 to 6.7) −28.7 (−33.3 to −9.1) −23.1 (−36.4 to −16.7)* 0.2 (−12.5 to 11.1) −32.3 (−42.4 to −18.3)*
IDL-C
Baseline 16.0 (13.0 to 20.0) 15.0 (12.0 to 19.0) 16.0 (13.0 to 20.0) 17.5 (12.0 to 20.0) 14.0 (11.0 to 20.0) 21.0 (14.0 to 22.0) 22.5 (17.5 to 26.0)
Post-treatmentb 15.0 (12.5 to 20.0) 7.0 (4.0 to 9.0) 11.5 (9.0 to 16.0) 8.0 (6.0 to 10.0) 6.0 (5.0 to 8.0) 20.0 (16.0 to 24.0) 8.0 (5.5 to 9.5)
% change from baseline −2.9 (−16.5 to 12.7) −53.9 (−63.6 to −50.0)** −22.5 (−42.1 to 7.1) −51.5 (−63.6 to −37.5)* −57.1 (−72.7 to −41.7)** −10.0 (−27.3 to–15.8) −68.6 (−73.1 to −49.2)**
Triglycerides
Baseline 132.0 (104.0 to 204.5) 148.0 (102.0 to 194.0) 135.0 (102.0 to 154.0) 149.5 (99.0 to 179.0) 124.0 (90.0 to 149.0) 140.5 (100.0 to 211.0) 131.5 (109.5 to 179.0)
Post-treatmentb 143.0 (115.0 to 210.5) 94.0 (78.0 to 152.0) 119.0 (87.0 to 180.0) 117.0 (86.0 to 162.0) 92.0 (72.0 to 116.0) 140.0 (93.0 to 162.0) 114.5 (99.0 to 144.0)
% change from baseline 2.4 (−15.9 to 33.9) −21.7 (−36.8 to 3.4)* −11.6 (−29.8 to 22.5) −13.5 (−31.3 to 18.6) −24.6 (−39.0 to −8.4)* −7.0 (−26.3 to 6.6) −22.2 (−31.3 to −1.9)
RLP-Cc
Baseline 30.0 (26.0 to 37.0) 29.0 (24.0 to 35.0) 32.5 (24.0 to 40.0) 33.0 (24.0 to 36.0) 25.0 (21.0 to 35.0) 36.0 (28.0 to 43.0) 37.5 (30.5 to 44.5)
Post-treatmentb 29.0 (25.0 to 38.0) 18.0 (13.0 to 20.0) 24.0 (18.0 to 32.0) 19.0 (17.0 to 22.0) 16.0 (14.0 to 18.0) 36.0 (32.0 to 39.0) 18.5 (15.0 to 22.0)
% change from baseline −4.4 (−14.5 to 9.3) −42.1 (−50.0 to −34.5)** −17.7 (−31.4 to 9.5) −38.7 (−50.0 to −26.7)* −42.1 (−55.0 to −29.4)** −8.5 (−18.8 to 18.2) −52.5 (−61.3 to −34.1)**
Values are median (Q1:Q3), mg/dL. *p < 0.05; **p < 0.0001. a,bSee footnotes to Table 2. cRLP-C consists of VLDL3-C + IDL-C. Q2W every 2 weeks, ATV atorvastatin, IDL-C intermediate-density lipoprotein cholesterol,















apoCIII/VLDL-C ratios do not change significantly on
therapy vs. baseline suggests alirocumab does not impact
the synthesis of apoCII or apoCIII.
Limitations of the current analysis include its post hoc na-
ture; the findings should be regarded as hypothesis-generat-
ing. In addition, overall patient numbers were relatively
small and patients were treated for a limited duration. Al-
though the study populations represent typical patients be-
ing treated for heFH or non-FH, there were few patients
with diabetes (11 % of the randomised populations in the
three studies), hence it is not possible to confirm the effects
of alirocumab on lipoprotein fractions in such patients.
Analysis of effects of lipid-modifying therapies on LDL-C
particle composition may aid understanding of treatment
mode-of-action as well as further understanding of the de-
rived clinical benefit of the treatment. However, the clinical
utility of measuring lipoprotein subfractions in risk assess-
ment remains to be elucidated, and current guidelines do
not advocate such an approach because of a lack of sup-
portive clinical trial data [6].
Conclusions
To conclude, in this post hoc analysis of three Phase II
trials, alirocumab 150 mg Q2W reduced cholesterol across
the spectrum of atherogenic lipoproteins separated by VAP
(including LDL, IDL and VLDL subfractions). Reductions
were consistent in both patients with heFH and primary
hyperlipidaemia. The potential clinical impact of alirocu-
mab on these lipid variables warrants further investigation.
Alirocumab is being assessed in the Phase III ODYSSEY
clinical trial program (https://clinicaltrials.gov/).
Methods
Patient samples from three Phase II multicentre, double-
blind, parallel-group, placebo-controlled trials were used
in this analysis: study 565 (NCT01288443) [14] and
study 566 (NCT01288469) [15] in patients with non-
familial hypercholesterolaemia (non-FH) and study 1003
(NCT01266876) [16] in patients with heterozygous familial
hypercholesterolaemia (heFH). Studies 565 and 1003 had a
12-week double blind period; study 566 had an 8-week
double blind period. All were multicenter trials conducted
in the US (study 1003 was also conducted in Canada). The
study protocols were approved by the institutional review
boards at each study center and appropriate ethical ap-
proval was obtained. Written informed consent was ob-
tained from all participants in the studies. Patients with
LDL-C ≥2.59 mmol/L (100 mg/dL) at baseline on statins
(± ezetimibe in study 1003) were treated with subcutane-
ous alirocumab 50–150 mg every 2 weeks (Q2W) or
150–300 mg every 4 weeks, depending on the study.
The 150 mg Q2W alirocumab dose was common to all
three trials and is the focus of this analysis.
Background statin was stable in studies 565 and 1003.
Study 566 comprised three treatment arms: alirocumab 150
mg Q2W plus atorvastatin 10 mg, alirocumab 150 mg Q2W
with atorvastatin dose increase from 10 to 80 mg at random-
isation, and placebo with the same atorvastatin dose increase.
Measurement methodology
Cholesterol content of major lipoproteins and subfractions
was analysed using VAP (Atherotech Diagnostics Labora-
tory, Birmingham, AL, USA). VAP is a validated technique
that separates lipoproteins based on density by single
vertical-spin density gradient ultracentrifugation [10, 11].
The amount of cholesterol of each lipoprotein and subfrac-
tion is quantified using a continuous flow analyser and a
cholesterol-specific enzymatic/spectrophotometric method.
The accuracy and reproducibility of the VAP method are
within the requirements of the US Centers for Disease
Control-National Heart, Lung, and Blood Institute Lipid
Standardization Program [10, 11] and comply with the
standards established by the National Cholesterol Educa-
tion Program guidelines [9]. Accuracy of the VAP method
Table 4 Changes from baseline in apoCII and apoCIII
Study 565 Study 566a Study 1003
Placebo Alirocumab 1
50 mg Q2W
Placebo + ATV 80 mg Alirocumab 150 mg
Q2W + ATV 10 mg
Alirocumab 150 mg
Q2W + ATV 80 mg
Placebo Alirocumab
150 mg Q2W
n = 30 n = 28 n = 27 n = 26 n = 29 n = 14 n = 16
ApoCII
Baseline 4.7 (2.1) 5.0 (2.1) 5.0 (1.8) 4.9 (2.1) 5.3 (2.0) 4.8 (2.3) 4.4 (1.9)
Post- treatmentb 5.3 (2.8) 3.8 (1.4) 4.3 (1.8) 4.2 (1.4) 3.7 (1.8) 4.7 (2.0) 3.7 (1.0)
% change from baseline 12.7 (32.6) −18.2 (28.3)** −7.6 (36.3) −8.8 (23.0) −27.8 (20.6)* 1.6 (15.5) −9.4 (28.1)
ApoCIII
Baseline 11.0 (4.0) 10.5 (3.2) 11.0 (4.6) 11.2 (4.1) 11.5 (4.5) 12.3 (4.5) 11.5 (4.7)
Post- treatmentb 12.2 (6.1) 8.6 (2.5) 10.0 (3.5) 9.8 (2.7) 8.9 (3.1) 11.6 (3.2) 9.4 (2.3)
% change from baseline 12.1 (37.5) −16.1 (20.1)** −2.0 (34.1) −9.4 (19.5) −19.1 (17.7)* −1.8 (19.3) −14.5 (19.7)
Values are mean (SD), units are mg/dL. *p < 0.05; **p < 0.0001.a,bSee footnotes to Table 2. Q2W every 2 weeks, apo apolipoprotein, ATV atorvastatin, SD
standard deviation
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is monitored on an on-going basis by split-sample
comparisons with results obtained using beta quantifi-
cation at the Core Laboratories for Clinical Studies at
Washington University, St. Louis, MO [9, 31].
Total LDL-C was determined as the directly measured
equivalent of the original definition by Friedewald [32]
representing non-HDL-C minus VLDL-C, the sum of
cholesterol carried in biologic or “real” LDL (LDLr-C),
and IDL (IDL-C). LDLr-C was further separated into four
subfractions using VAP: LDL1-C, LDL2-C, LDL3-C, and
LDL4-C (increasing in density from subclass 1 through 4).
The two densest subfractions, LDL3-C and LDL4-C, were
analysed individually and also pooled (LDL3+4-C), repre-
senting the sum of dense LDL subfraction cholesterol since
LDL4-C typically exists at substantially lower concentra-
tions than the other three LDL subfractions. LDL1-C and
LDL2-C were also pooled, representing the sum of the
more buoyant, lower density LDL subfraction cholesterol.
Other lipoproteins measured using VAP included VLDL-C
and its subfractions VLDL1-C, VLDL2-C, and VLDL3-C
(again, increasing in density from subclass 1 through 3),
IDL-C and its subfractions IDL1−C and IDL2−C (with
subclass 2 being more dense), and total RLP cholesterol
(RLP-C, comprising VLDL3-C + IDL-C).
The ratio of apoB to apoAI levels was calculated based
on measurements determined in the respective parent
studies using conventional techniques, as were triglycer-
ide levels [14–16]. ApoCII and apoCIII concentrations
were measured at Atherotech Diagnostics Laboratory
(Birmingham, AL, USA) using reagent kits obtained from
Randox Laboratories Limited, UK (apoCII, Cat. No.
LP3866; apoCIII, Cat. No. LP3865) and an Architect ci8200
analyser (Abbott Laboratories). The immunoassay methods
are based on the reaction of a sample containing human
apoCII (or CIII) and specific antiserum to apoCII (or CIII)
to form an insoluble complex, the concentration of which
can be measured turbidimetrically at 340 nm. Both assays
were validated for analytical performance.
Statistical analyses
All statistical analyses were performed using R version
3.0.2. Mean levels of cholesterol in lipoprotein fractions
and subfractions, triglycerides, apoCII and apoCIII, and
the apoB/apoA1 ratio were assessed in patients receiving
alirocumab 150 mg Q2W vs. placebo at baseline and at
Week 12 for study 565, Week 8 for study 566 and Week
6 for study 1003. Study 1003 had a Week 12 endpoint;
however, 6-week data were used for this analysis due to
reduced numbers of patients with available samples at
12 weeks (n = 17; all dosing groups) compared with
6 weeks (n = 75; all dosing groups). To determine if per-
centage changes from baseline to the 6–12 week time
points were significant for alirocumab vs. placebo, ana-
lysis of covariance was performed with the baseline value
as a covariate. Significance is considered at alpha ≤0.05.
P-values were not adjusted for multiplicity and are pre-
sented for descriptive purposes only.
Additional file
Additional file 1: Table S1. Changes from baseline in lipids and
lipoproteins as measured using conventional methods in the parent
studies. Table S2. Change from baseline in apoB/apoAI ratio. Table S3.
Changes from baseline in ratios of apoCII/VLDL-C and apoCIII/VLDL-C.
Table S4. Pooled data from across the three studies (565, 566, 1003) for
changes from baseline in cholesterol content of lipoprotein subfractions,
apoB/apoA1 ratio, and levels of apo CII and CIII. (DOCX 45 kb)
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